Potential Cytochrome P450 (CYP) Drug Interactions
List of drugs that may have potential CYP1A2 interactions
CYP1A2 Substrates
|Acenocoumarol |Duloxetine |Estropipate |Ropinirole |
|Aminophylline |Estradiol |Flutamide |Tacrine |
|Betaxolol |Estrogens, conjugated |Fluvoxamine |Theophylline |
|Caffeine |(synthetic) |Guanabenz |Thiothixene |
|Clomipramine |Estrogens, conjugated |Mexiletine |Trifluoroperazine |
|Clozapine |(equine) |Mirtazapine | |
|Cyclobenzaprine |Estrogens, conjugated |Pimozide | |
|Dacarbazine |(esterified) |Propanolol | |
|Doxepin |Estrone |Riluzole | |
CYP 1A2 Inhibitors
|Albendazole |Erythromycin |Methimazole |Propafenone |
|Alosetron |Estradiol |Methoxsalen |Propofol |
|Amiodarone |Estrogens, conjugated |Mexiletine |Propanolol |
|Amitriptyline |(synthetic) |Miconazole |Ranitidine |
|Amlodipine |Estrogens, conjugated |Mirtazapine |Rofecoxib |
|Anastrozole |(equine) |Moclobemide |Ropinirole |
|Atazanavir |Ethinyl estradiol |Modafinil |Selegiline |
|Bortezomib |Fluconazole |Nalidixic acid |Sertraline |
|Bromocriptine |Fluoxetine |Nefazodone |Sildenafil |
|Buprenorphine |Fluphenazine |Nelfinavir |Sulconazole |
|Caffeine |Flutamide |Nevirapine |Tacrine |
|Cimetidine |Fluvastatin |Nifedipine |Tenofovir |
|Ciprofloxacin |Fluvoxamine |Nisoldipine |Theophylline |
|Citalopram |Gemfibrozil |Norfloxacin |Thiabendazole |
|Clarithromycin |Ginseng (2) |Ofloxacin |Thioridazine |
|Clotrimazole |Imipramine |Olanzapine |Ticlopidine |
|Clozapine |Interferon-α2a |Omeprazole |Tioconazole |
|Delavirdine |Interferon-α2b |Ondansetron |Tocainide |
|Dexmedetomidine |Interferon-γ1b |Orphenadrine |Tranylcypromine |
|Diclofenac |Isoniazid |Paroxetine |Verapamil |
|Disulfiram |Ketoconazole |Peginterferon-α2a |Zafirlukast |
|Drospirenone |Lidocaine |Peginterferon-α2b |Zileuton |
|Echinacea (1) |Lomefloxacin |Pentoxifylline | |
|Enoxacin |Losartan |Perphenazine | |
|Entacapone |Mestranol |Primaquine | |
CYP1A2 Inducers
|Aminoglutethimide |Phenobarbital |Primidone |Rifampin |
|Carbamazepine | | | |
When drugs classified as ‘substrates’ are co-administered with (Study Agent), there is the potential for higher concentrations of the ‘substrate’. When (Study Agent) is co-administered with compounds classified as ‘inhibitors’, increased plasma concentrations of (Study Agent) is the potential outcome. The co-administration of ‘inducers’ would potentially lower plasma (Study Agent) concentrations.
Note: Adapted from Cytochrome P450 Enzymes: Substrates, Inhibitors, and Inducers. In: Lacy CF, Armstrong LL, Goldman MP, Lance LL eds. Drug Information Handbook 15TH ed. Hudson, OH; LexiComp Inc. 2007: 1899-1912.
Only major substrates and effective inducers are listed.
Additional information for drug interactions with cytochrome P450 isoenzymes can be found at .
(1) Gorski, et al. (2004). Clin Pharmacol Ther. 75:89-100.
(2) Saruwatari, et al. (2003). J Pharm Pharmacol. 55:1553-1559.
Updated on May 1, 2007
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related searches
- drug interactions ranitidine
- interactions for ranitidine hcl
- ranitidine interactions with other medicines
- drug interactions with mao inhibitors
- viagra drug interactions list
- zyrtec drug interactions up to date
- drug interactions zyrtec and benadryl
- gabapentin drug interactions with metformin
- major drug interactions with warfarin
- common drug interactions pdf
- most common drug interactions list
- drug interactions lookup